Appili Therapeutics Inc. APLIF
0.00 USD -0.01 (-71.43%)
At closeNov 3, 2026, 4:00 PM EST
0.004 Day range 0.0068
0.004 52-week range 0.02
- YTD
- -86.67%
- 1 year
- -88.89%
- Market cap
- 264.73K
- EPS (ttm)
- -0.11
- YTD return
- -86.67%
- 1-year return
- -88.89%
- Volume
- 36.65K
- Avg volume
- 5.49K
- Open
- 0.004
- Previous close
- 0.007
- Day's range
- 0.004 – 0.0068
- 52-week range
- 0.004 – 0.02
- Earnings date
- Feb 11, 2025
YTD -0.0080 (-53.33%)
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| Jun 25, 2024 | Mar 1, 2024 | -0.01 | -0.01 | 0.00 | 0.00% |
| Feb 13, 2024 | Dec 1, 2023 | -0.01 | 0.00 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.01 | -0.01 | 0.00 | 0.00% |
News
Appili Therapeutics Announces Transfer to NEX 
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027 
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program 
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results 
Appili Therapeutics to Exhibit at World Vaccine Congress Washington 
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement 
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026 
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026 
Appili Therapeutics to Attend BARDA Innovation Symposium 2025 
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Your note
Sign in to keep a note on APLIF — it syncs with the Stock Master app.